Changes in protein profiles of multiple myeloma cells in response to bortezomib

References

• Raab MS, Podar K, Breitkreutz I, . Multiple myeloma. Lancet 2009;374:324–339.
   PubMed Web of Science ®Google Scholar
• Zaidi AA, Vesole DH. Multiple myeloma: an old disease with new hope for the future. CA Cancer J Clin 2001;51:273–285.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, . Cancer statistics. CA Cancer J Clin 2007;57:43–66.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Creixenti JB, Garcia-Sanz R. Treatment of multiple myeloma. Haematologica 1999;84:36–58.
   PubMed Web of Science ®Google Scholar
• Collins CD. Problems monitoring response in multiple myeloma. Cancer Imag 2005;5(Spec. no. A):S119–S126.
   Google Scholar
• Pandit SR. Multiple myeloma: treatment options for an incurable disease. J Assoc Physicians India 2005;53:1060–1064.
   PubMedGoogle Scholar
• Dmoszyńska A. Diagnosis and the current trends in multiple myeloma therapy. Pol Arch Med Wewn 2008;118:563–566.
   PubMedGoogle Scholar
• Mateos MV, San Miguel JF. Bortezomib in multiple myeloma. Best Pract Res Clin Haematol 2007;20:701–715.
   PubMed Web of Science ®Google Scholar
• Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol 2001;116:637–646.
   PubMed Web of Science ®Google Scholar
• Blade J, Cibeira MT, Rosinol L. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Acta Oncol 2005; 44:440–448.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003;10: 361–369.
   PubMedGoogle Scholar
• Voorhees PM, Dees EC, O’Neil B, . The proteasome as a target for cancer therapy. Clin Cancer Res 2003;9:6316–6325.
   PubMed Web of Science ®Google Scholar
• Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004;22:304–311.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Hideshima T, Mitsiades C, . Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005;4:686–692.
   PubMed Web of Science ®Google Scholar
• Matthews W, Driscoll J, Tanaka K, . Involvement of the proteasome in various degradative processes in mammalian cells. Proc Natl Acad Sci USA 1989;86:2597–2601.
   PubMed Web of Science ®Google Scholar
• Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82:373–428.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Akiyama M, . Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530–1534.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Fonseca R, Chesi M, . Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131–144.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Davis RE, Demchenko Y, . Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115–130.
   PubMed Web of Science ®Google Scholar
• Ma MH, Yang HH, Parker K, . The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136–1144.
   PubMed Web of Science ®Google Scholar
• Richardson P. Clinical update:proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 2003;29:33–39.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Anderson KC. Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol 2003;1:596–600.
   PubMedGoogle Scholar
• Orlowski RZ, Baldwin AS Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol Med 2002;8:385–389.
   PubMed Web of Science ®Google Scholar
• Baran Y, Salas A, Senkal CE, . Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007;282:10922–10934.
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
   PubMed Web of Science ®Google Scholar
• Lin JF, Chen QX, Tian HY, . Stain efficiency and MALDI-TOF MS compatibility of seven visible staining procedures. Anal Bioanal Chem 2008;390:1765–1773.
   PubMed Web of Science ®Google Scholar
• Shevchenko A, Wilm M, Vorm O, . Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996;68:850–858.
   PubMed Web of Science ®Google Scholar
• Arndt B, Krieger T, Kalinski T, . The transmembrane adaptor protein SIT inhibits TCR-mediated signaling. PloS One 2011;6:e23761.
   PubMed Web of Science ®Google Scholar
• Tedoldi S, Paterson JC, Hansmann ML, . Transmembrane adaptor molecules: a new category of lymphoid-cell markers. Blood 2006;107:213–221.
   PubMed Web of Science ®Google Scholar
• Marie-Cardine A, Kirchgessner H, Bruyns E, . SHP2-interacting transmembrane adaptor protein (SIT), a novel disulfide-linked dimer regulating human T cell activation. J Exp Med 1999;189:1181–1194.
   PubMed Web of Science ®Google Scholar
• Salgia R, Li JL, Lo SH, . Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem 1995;270:5039–5047.
   PubMed Web of Science ®Google Scholar
• Bertin J, Wang L, Guo Y, . CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B. J Biol Chem 2001;276:11877–11882.
   PubMed Web of Science ®Google Scholar
• Hirotani T, Lee PY, Kuwata H, . The nuclear IkappaB protein IkappaBNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria. J Immunol 2005;174:3650–3657.
   PubMed Web of Science ®Google Scholar
• Gilmore TD. Introduction to NF-kappaB:players, pathways, perspectives. Oncogene 2006;25:6680–6684.
   PubMed Web of Science ®Google Scholar
• Brasier AR. The NF-kappaB regulatory network. CardiovascToxicol 2006;6:111–130.
   Google Scholar
• Xue L, Chu F, Cheng Y, . Siva-1 binds to and inhibits BCL-X(L)-mediated protection against UV radiation-induced apoptosis. Proc Natl Acad Sci USA 2002;99:6925–6930.
   PubMed Web of Science ®Google Scholar
• Gudi R, Barkinge J, Hawkins S, . Siva-1 negatively regulates NF-kappaB activity:effect on T-cell receptor-mediated activation-induced cell death (AICD). Oncogene 2006;25:3458–3462.
   PubMed Web of Science ®Google Scholar
• Hooi CF, Blancher C, Qiu W, . ST7-mediated suppression of tumorigenicity of prostate cancer cells is characterized by remodeling of the extracellular matrix. Oncogene 2006;25:3924–3933.
   PubMed Web of Science ®Google Scholar
• Xu Z, Maroney AC, Dobrzanski P, . The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Mol Cell Biol 2001;21:4713–4724.
   PubMed Web of Science ®Google Scholar
• Pearson G, Robinson F, Beers Gibson T, . Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153–183.
   PubMed Web of Science ®Google Scholar
• Hu MC, Qiu WR, Wang X, . Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade. Genes Dev 1996;10:2251–2264.
   PubMed Web of Science ®Google Scholar
• Kim SH, Han SY, Azam T, . Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005;22:131–142.
   PubMed Web of Science ®Google Scholar
• Mills GC. Hemoglobin catabolism. I. Glutathione peroxidase, an erythrocyte enzyme which protects hemoglobin from oxidative breakdown. J Biol Chem 1957;229:189–197.
   PubMed Web of Science ®Google Scholar
• Nicholson DW, Ali A, Thornberry NA, . Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37–43.
   PubMed Web of Science ®Google Scholar
• Jin L, Williamson A, Banerjee S, . Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex. Cell 2008;133:653–665.
   PubMed Web of Science ®Google Scholar
• Cheng KW, Lahad JP, Kuo WL, . The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 2004;10:1251–1256.
   PubMed Web of Science ®Google Scholar
• Bakker AB, Baker E, Sutherland GR, . Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc Natl Acad Sci USA 1999;96:9792–9796.
   PubMed Web of Science ®Google Scholar
• Ben-Zvi T, Yayon A, Gertler A, . Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. J Cell Sci 2006;119:380–387.
   PubMed Web of Science ®Google Scholar
• Minamoto S, Ikegame K, Ueno K, . Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem Biophys Res Commun 1997;237:79–83.
   PubMed Web of Science ®Google Scholar
• Stehlik C, Krajewska M, Welsh K, . The PAAD/PYRIN- only protein POP1/ASC2 is a modulator of ASC-mediated nuclear-factor-kappa B and pro-caspase-1 regulation. Biochem J 2003;373:101–113.
   PubMed Web of Science ®Google Scholar
• Ballinger CA, Connell P, Wu Y, . Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol 1999;19:4535–4545.
   PubMed Web of Science ®Google Scholar
• Ishikawa J, Kaisho T, Tomizawa H, . Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 1995;26:527–534.
   PubMed Web of Science ®Google Scholar
• Yu G, Boone T, Delaney J, . APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 2000;1:252–256.
   PubMed Web of Science ®Google Scholar
• Hatzoglou A, Roussel J, Bourgeade MF, . TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol 2000;165:1322–1330.
   PubMed Web of Science ®Google Scholar
• Fukunaga R, Hunter T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J 1997;16:1921–1933.
   PubMed Web of Science ®Google Scholar
• Knauf U, Tschopp C, Gram H. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol 2001;21:5500–5511.
   PubMed Web of Science ®Google Scholar